Details of the Drug Combination

General Information of Drug Combination (ID: DCZ3OD9)

Drug Combination Name
Sutezolid Bedaquiline
Indication
Disease Entry Status REF
Tuberculosis Phase 2 [1]
Component Drugs Sutezolid   DM2KQ71 Bedaquiline   DM3906J
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sutezolid
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B1Z Phase 2 [2]
Sutezolid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Protein synthesis (Bact PROS) TT2VX74 NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Sutezolid Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Bedaquiline
Disease Entry ICD 11 Status REF
Drug-resistant tuberculosis N.A. Approved [3]
Multi-drug resistant tuberculosis MG52.00 Approved [4]
Pulmonary tuberculosis 1B10.Z Approved [3]
Bedaquiline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Proton pump (MycB Prop) TT19K0L A0A1Q4HQH4_9MYCO Modulator [7]
------------------------------------------------------------------------------------
Bedaquiline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Pulmonary Tuberculosis DCZSUT4 N. A. Phase 2 [9]
Tuberculosis DC5SDH7 N. A. Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05686356) A Pan-TB Regimen Targeting Host and Microbe
2 ClinicalTrials.gov (NCT01225640) A Study Of PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary Tuberculosis To Assess Early Bactericidal Activity (EBA) And Whole Blood Activity (WBA). U.S. National Institutes of Health.
3 Bedaquiline FDA Label
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59.
6 TB and HIV therapeutics: pharmacology research priorities. AIDS Res Treat. 2012;2012:874083.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
9 ClinicalTrials.gov (NCT05807399) PanACEA - STEP2C -01